Benralizumab meets both co-primary endpoints of reduced nasal polyp size and blockage in OSTRO Phase III trial in patients with chronic rhinosinusitis with nasal polyps

AstraZeneca announced benralizumab demonstrated statistically significant improvement in endoscopic total nasal polyp score and nasal blockage score vs. placebo, in symptomatic patients with severe bilateral nasal polyposis despite continued treatment with standard of care.

SPS commentary:

Benralizumab, a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils, is currently licensed as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonist.


AstraZeneca Plc.